<DOC>
	<DOCNO>NCT01075113</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together sorafenib tosylate treat patient advanced liver cancer . Sorafenib tosylate vorinostat may stop growth tumor cell block enzymes need cell growth block blood flow tumor .</brief_summary>
	<brief_title>Sorafenib Vorinostat Treating Patients With Advanced Liver Cancer</brief_title>
	<detailed_description>Outline : This dose-escalation study vorinostat . The purpose research study test safety effectiveness combination two cancer drug , sorafenib ( Nexavar ) vorinostat ( Zolinza ) , advance liver cancer ( hepatocellular carcinoma ) . Advanced mean cancer spread far consider surgery . Approximately 19 people take part study . After enrollment 6 patient sorafenib 400 mg orally twice day vorinostat 300 mg orally , 2 6 patient evaluable DLT ( DLTs ) . The 4 patient evaluable DLT require dose modification . Because dose modification need , Cohort A modify include 2 dose level : Dose level A-1a ( sorafenib 400 mg orally twice day vorinostat 200 mg orally day ) dose level A1 ( sorafenib 400 mg orally twice day vorinostat 100 mg orally day ) . The start dose upon reopen approval version dose level A-1a . Dose level A1 use dose level A-1a tolerable .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis HCC biopsyproven pathologic diagnosis clinical criterion define : * Clinical criterion meet patient history cirrhosis chronic hepatitis B infection : Imaging abnormality &gt; 1 cm size classic enhancement magnetic resonance imaging ( MRI ) triplephase compute tomography ( CT ) scan Alphafetoprotein ( AFP ) value Performance status Eastern Cooperative Oncology Group ( ECOG ) = &lt; 1 If cirrhosis , ChildPugh classification A B Total bilirubin = &lt; 3.0 mg/dL Creatinine = &lt; 1.5 x upper limit normal laboratory International normalized ratio ( INR ) = &lt; 1.7 ( due anticoagulant ) Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelets &gt; = 80,000/mm^3 Hemoglobin ( Hgb ) &gt; = 8.5 g/dL ( transfusion erythropoietinlike substance permit prior baseline evaluation ) Any prior therapy surgery , chemoembolization , radiofrequency ablation , alcohol injection allow long toxicity prior therapy = &lt; grade 1 Prior sorafenib allow long toxicity ongoing â‰¤ grade 2 prior intolerance 400 mg sorafenib PO daily felt amenable , principal investigator , supportive care measure dose modification . Measurable evaluable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criterion version ( v ) 1.1 mRECIST elevate AFP Ability understand willingness sign write informed consent ; sign informed consent must obtain prior study specific procedure Women childbearing potential must negative pregnancy test perform within 2 week prior start treatment Women childbearing potential men must agree use medically accept form birth control duration study participation 4 month follow completion study treatment Candidate curative therapy include surgical resection orthotopic liver transplantation Known central nervous system metastasis Any investigational agent within 4 week first dose study treatment Known intolerance vorinostat Unable swallow medication Unable swallow medication ; suspect malabsorption Active alcohol abuse Contraindication antiangiogenic agent , include : Pulmonary hemorrhage/bleeding event &gt; = grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event &gt; = grade 3 within 4 week first dose study treatment Serious nonhealing wound , ulcer , bone fracture Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month ; hepatic portal vein thrombus consider exclusion criterion Major cardiac dysfunction , uncontrolled angina , congestive heart failure New York Heart Association ( NYHA ) class III high , know leave ventricular ejection fraction le 40 % Systolic blood pressure &gt; 160 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management Significant lung disease ( oxygen [ O2 ] saturation le 88 % room air ) Serious uncontrolled infection ; know human immunodeficiency virus ( HIV ) seropositivity require retroviral therapy , diagnosis acquire immune deficiency syndrome ( AIDS ) ; diagnosis chronic hepatitis B C allow Medical , psychological , social condition , opinion investigator , may increase patient 's risk interfere patient 's participation study hinder evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>